BR112018077430A2 - composição farmacêutica. - Google Patents

composição farmacêutica.

Info

Publication number
BR112018077430A2
BR112018077430A2 BR112018077430-8A BR112018077430A BR112018077430A2 BR 112018077430 A2 BR112018077430 A2 BR 112018077430A2 BR 112018077430 A BR112018077430 A BR 112018077430A BR 112018077430 A2 BR112018077430 A2 BR 112018077430A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
gel
benzidamine
vulvovaginitis
vaginosis
Prior art date
Application number
BR112018077430-8A
Other languages
English (en)
Inventor
Fazio Antonello
Tongiani Serena
Donati Luca
Milanese Claudio
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A
Publication of BR112018077430A2 publication Critical patent/BR112018077430A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere a uma composição farmacêutica em creme, creme-gel ou gel compreendendo benzidamina que tem tolerabilidade e eficácia melhoradas para a prevenção e ao tratamento de condições inflamatórias e/ou infecciosas principalmente localizadas na área genital, em particular vaginose, vaginite e vulvovaginite.
BR112018077430-8A 2016-07-08 2017-07-03 composição farmacêutica. BR112018077430A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16178742.9 2016-07-08
EP16178742 2016-07-08
PCT/EP2017/066438 WO2018007288A1 (en) 2016-07-08 2017-07-03 Pharmaceutical composition comprising benzydamine

Publications (1)

Publication Number Publication Date
BR112018077430A2 true BR112018077430A2 (pt) 2019-04-02

Family

ID=56408999

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018077430-8A BR112018077430A2 (pt) 2016-07-08 2017-07-03 composição farmacêutica.

Country Status (25)

Country Link
US (1) US20190224168A1 (pt)
EP (1) EP3481370B1 (pt)
JP (1) JP7060526B2 (pt)
KR (1) KR20190026686A (pt)
CN (1) CN109562058A (pt)
AR (1) AR109254A1 (pt)
AU (1) AU2017294402A1 (pt)
BR (1) BR112018077430A2 (pt)
CA (1) CA3025863A1 (pt)
CY (1) CY1124250T1 (pt)
DK (1) DK3481370T3 (pt)
EA (1) EA037435B1 (pt)
ES (1) ES2877133T3 (pt)
HR (1) HRP20210762T1 (pt)
HU (1) HUE054775T2 (pt)
IL (1) IL264083A (pt)
LT (1) LT3481370T (pt)
MD (1) MD3481370T2 (pt)
MX (1) MX2018015637A (pt)
PL (1) PL3481370T3 (pt)
PT (1) PT3481370T (pt)
RS (1) RS62022B1 (pt)
SG (1) SG11201900033UA (pt)
SI (1) SI3481370T1 (pt)
WO (1) WO2018007288A1 (pt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69011557T2 (de) 1989-03-31 1995-03-23 Lepetit Spa Verwendung von Purpuromycin zur Behandlung von Vaginalinfektionen.
CA2009402A1 (en) * 1990-02-06 1991-08-06 Attilio J. De Sanctis Use of benzydamine and salts thereof for relief of pain associated with herpes viral infections and laser vaporization of condylomata
GB9610359D0 (en) 1996-05-17 1996-07-24 Edko Trading Representation Pharmaceutical compositions
US6913759B2 (en) * 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
ITMI20031640A1 (it) * 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
EP1698336A1 (en) * 2005-03-01 2006-09-06 Ferrer Internacional, S.A. Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent
ITBO20050388A1 (it) * 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
US20070264309A1 (en) 2006-01-20 2007-11-15 Chollet Janet A Method Of Treating Atrophic Vaginitis
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
ITMI20071136A1 (it) 2007-06-04 2008-12-05 Velleja Res Srl Formulazioni topiche per la prevenzione e il trattamento degli stati infiammatori e/o infettivi dell'aera genitale
CN101219139A (zh) * 2007-12-24 2008-07-16 广西壮族自治区花红药业股份有限公司 盐酸苄达明栓剂及其制备方法
CN101214218A (zh) * 2007-12-26 2008-07-09 广西壮族自治区花红药业股份有限公司 盐酸苄达明凝胶剂及其制备方法
CN102470125B (zh) * 2009-07-08 2015-08-19 方济各安吉利克化学联合股份有限公司 苄达明在制备治疗p40-依赖性疾病的药物中的用途
WO2013178749A1 (fr) * 2012-06-01 2013-12-05 Galderma Research & Development Nanocapsules lipidiques comprenant un rétinoide, nanodispersion et composition les contenant, leur procédé de préparation et leur utilisation en dermatologie
US10806697B2 (en) * 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2016113194A1 (en) 2015-01-13 2016-07-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pharmaceutical composition for the treatment of mycosis

Also Published As

Publication number Publication date
EA201990160A1 (ru) 2019-06-28
JP7060526B2 (ja) 2022-04-26
RS62022B1 (sr) 2021-07-30
DK3481370T3 (da) 2021-06-07
SG11201900033UA (en) 2019-02-27
PT3481370T (pt) 2021-05-28
PL3481370T3 (pl) 2021-10-11
HRP20210762T1 (hr) 2021-06-25
AR109254A1 (es) 2018-11-14
HUE054775T2 (hu) 2021-09-28
KR20190026686A (ko) 2019-03-13
EA037435B1 (ru) 2021-03-26
AU2017294402A1 (en) 2018-12-20
US20190224168A1 (en) 2019-07-25
IL264083A (en) 2019-01-31
MX2018015637A (es) 2019-06-17
WO2018007288A1 (en) 2018-01-11
MD3481370T2 (ro) 2021-08-31
CN109562058A (zh) 2019-04-02
JP2019520370A (ja) 2019-07-18
LT3481370T (lt) 2021-08-25
EP3481370B1 (en) 2021-03-24
CY1124250T1 (el) 2022-07-22
EP3481370A1 (en) 2019-05-15
CA3025863A1 (en) 2018-01-11
SI3481370T1 (sl) 2021-08-31
ES2877133T3 (es) 2021-11-16

Similar Documents

Publication Publication Date Title
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
MA41013A (fr) Compositions comprenant des souches bactériennes
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
PE20150199A1 (es) Composiciones farmaceuticas y tratamiento de mastitis
BR112015018827A2 (pt) composição farmacêutica oral para tratamento de mucosite oral e estomatite
EP3586853A4 (en) PHARMACEUTICAL COMPOSITION CONSISTING OF MESENCHYMATIC STEM CELL STIMULATED BY INFLAMMATION FOR THE PREVENTION OR TREATMENT OF IMMUNE OR INFLAMMATORY DISEASE
PH12017500637A1 (en) Inhibitors of lysine gingipain
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP3378491A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF NASH
IN2013MU03373A (pt)
BR112017005272A2 (pt) uso de cisteamina no tratamento de infecções causadas por leveduras/bolores
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
ZA201907487B (en) Compositions and treatment procedures for the treatment of pathogenic infections
EP3292872C0 (en) COMPOSITION FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY INFECTIOUS DISEASES OR COMPOSITION FOR IMPROVING IMMUNITY COMPRISING TRYPTOPHANYL-ARNT SYNTHETASE AS ACTIVE PRINCIPLE
MX2017003360A (es) Composicion para la prevencion y/o tratamiento de sintomas de alergia.
IL257336B (en) Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases
BR112018077430A2 (pt) composição farmacêutica.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
EP3362085C0 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH MUCIN
BR112017014295A2 (pt) composição farmacêutica.
EA201591521A1 (ru) Композиция, содержащая арабиногалактан и полифенолы из лиственницы
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
ECSP16095540A (es) Composiciones antimicrobianas con agentes efervescentes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2729 DE 25-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.